The global multidrug-resistant tuberculosis epidemic has prompted efforts to develop new antimycobacterial compounds and strategies to improve efficacy and compliance of drugs already in use. Several antituberculous compounds require in situ metabolic activation to become inhibitory to the mycobacterium. Ethionamide, a thiocarbamide-containing drug, is activated by the mycobacterial mono-oxygenase EthA. The production of EthA is inhibited …